Sections
Excerpt
Monoamine oxidase inhibitors (MAOIs) were first identified as effective antidepressants in the late 1950s. An early report suggested that iproniazid, an antitubercular agent, had mood-elevating properties in patients who had been treated for tuberculosis (Bloch et al. 1954). Following these observations, two studies confirmed that iproniazid did indeed have antidepressant properties (Crane 1957; Kline 1958). Zeller (1963) showed that iproniazid caused potent inhibition of monoamine oxidase (MAO) enzymes both in vivo and in vitro in the brain. He also reported that the medication reversed some of the actions of reserpine. Because reserpine produced significant depression as a side effect, it was suggested that iproniazid might have mood-elevating properties.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
